Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acromeg...
Crinetics Pharmaceuticals reported revenue of $7.70 million for fiscal year 2025, up 640.7% from fiscal year 2024, and net income of -$465.32 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $25.12 million, up 2336.3% from a year before.
Figures from company filings; latest fiscal year ended December 31, 2025.
No profile data available.